Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Total Non-Current Liabilities across 13 years of filings, most recently posting $46.3 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $46.3 million, down 19.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.3 million (down 19.87% YoY), and the FY2025 annual result was $52.2 million, down 17.62% from the prior year.
• Total Non-Current Liabilities came in at $46.3 million for Q1 2026 at Rocket Pharmaceuticals, down from $52.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $70.8 million in Q4 2023 to a low of $42.5 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $56.0 million (2024), against an average of $56.0 million.
• Peak annual rise in Total Non-Current Liabilities reached 41.0% in 2022, while the deepest fall reached 55.93% in 2022.
• Rocket Pharmaceuticals' Total Non-Current Liabilities stood at $59.5 million in 2022, then increased by 18.99% to $70.8 million in 2023, then retreated by 10.6% to $63.3 million in 2024, then retreated by 17.62% to $52.2 million in 2025, then dropped by 11.24% to $46.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $46.3 million (Q1 2026), $52.2 million (Q4 2025), and $53.3 million (Q3 2025), per Business Quant data.